HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction.

AbstractBACKGROUND:
The incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing recently in both Western and Eastern countries. However, an optimal treatment strategy for Siewert type II AEG is still unclear. The aim of this study was to clarify the value of splenectomy in patients with Siewert type II AEG.
METHODS:
From September 2002 to November 2011, 42 patients underwent total gastrectomy with D2 lymph node dissection for Siewert type II AEG and were included in this study. We used the index of estimated benefit from lymph node dissection (IEBLD) to assess the efficacy of lymph node dissection of each station. Surgical complications were graded by the Clavien-Dindo classification.
RESULTS:
The overall 5-year survival rate of the 42 patients was 57.5 %. The incidence of splenic hilar lymph node metastasis was 4.8 % and the 5-year survival rate of patients with splenic hilar lymph node involvement was zero. Consequently, the IEBLD of splenic hilar lymph nodes was zero. Postoperative morbidities occurred in 25 patients (59.5 %). Pancreas-related complications were the most frequently observed (28.5 %), followed by intraabdominal abscess (14.3 %) and anastomotic leakage (9.5 %).
CONCLUSIONS:
Splenic hilar lymph node dissection may be omitted without decreasing curability in patients with Siewert type II AEG, although a prospective study is necessary for more conclusive results.
AuthorsHironobu Goto, Masanori Tokunaga, Norihiko Sugisawa, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Masahiro Niihara, Yasuhiro Tsubosa, Masanori Terashima
JournalGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Gastric Cancer) Vol. 16 Issue 4 Pg. 590-5 (Oct 2013) ISSN: 1436-3305 [Electronic] Japan
PMID23179369 (Publication Type: Journal Article)
Topics
  • Adenocarcinoma (mortality, pathology, surgery)
  • Adenocarcinoma, Mucinous (mortality, pathology, surgery)
  • Adenocarcinoma, Papillary (mortality, pathology, surgery)
  • Adult
  • Aged
  • Carcinoma, Signet Ring Cell (mortality, pathology, surgery)
  • Esophagogastric Junction (pathology, surgery)
  • Female
  • Follow-Up Studies
  • Gastrectomy
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (mortality, pathology, surgery)
  • Neoplasm Staging
  • Prognosis
  • Splenectomy
  • Stomach Neoplasms (mortality, pathology, surgery)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: